证券代码：600129 证券简称：太极集团 公告编号：2025-009 重庆太极实业（集团）股份有限公司 第十届监事会第二十一次会议决议公告 表决情况：同意 4 票，弃权 0 票，反对 0 票；表决结果：通过。 三、关于定增募投项目结项及终止并将剩余募集资金永久补充流 1 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）第十届监 事会第二十一次会议于 2025 年 2 月 25 日以邮件方式发出书面通知，于 2025 年 3 月 3 日以现场及视频方式召开。会议应到监事 4 人，实到监 事 4 人，公司董事会秘书列席了会议。本次会议的召集、召开程序符合 《公司法》和《公司章程》的有关规定，会议合法有效。会议审议并通 过了如下议案： 一、关于受让重庆太极麒灵电子商务有限公司 100%股权的议案 （具体内容详见公司披露的《太极集团关于受让下属子公司股权的公 告》；公告编号：2025-010） 为了进一步聚焦主业，理顺股权架构与管理关系，公司拟以现金 614 万元受让控股子公司重庆 ...

重庆太极实业（集团）股份有限公司（以下简称：公司）第十届 董事会第二十六次会议于 2025 年 2 月 25 日以邮件方式发出书面通知， 于 2025 年 3 月 3 日以现场及视频方式召开。本次会议由董事长俞敏 先生主持，会议应到董事 8 人，实到董事 8 人，公司监事和高级管理 人员列席了会议。本次会议的召集、召开程序符合《公司法》和《公 司章程》的有关规定，会议合法有效。会议审议并通过了如下议案： 一、关于受让重庆太极麒灵电子商务有限公司 100%股权的议案 （具体内容详见公司披露的《太极集团关于受让下属子公司股权的公 告》；公告编号：2025-010） 为了进一步聚焦主业，理顺股权架构与管理关系，公司拟以现金 614 万元受让控股子公司重庆桐君阁大药房连锁有限责任公司持有重 庆太极麒灵电子商务有限公司 100%的股权。 证券代码：600129 证券简称：太极集团 公告编号：2025-008 重庆太极实业（集团）股份有限公司 第十届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 表决情况： ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, focusing on innovation, overseas expansion, thematic investments, and dividend strategies as the main investment themes [2][17]. Core Insights - The pharmaceutical sector experienced a short-term pullback but remains optimistic about the innovation-driven growth trajectory. Key areas of focus include innovative drugs, international market expansion, and supportive policies for innovation [2][17]. - The report highlights the importance of innovative drugs as a new productive force, with significant policy support expected to accelerate their development [17]. - The report emphasizes the potential of companies with strong clinical pipelines and innovative capabilities, particularly in the context of recent supportive policies for innovative drugs [16][17]. Summary by Sections Current Industry Investment Strategy - The pharmaceutical index fell by 2.72% in the week, underperforming the CSI 300 index by 1.97 percentage points. Year-to-date, the sector has risen by 1.11%, outperforming the CSI 300 by 1.75 percentage points [15]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 26.53 times, with a premium of 75.91% relative to the entire A-share market [15]. Key Companies and Their Performance - **Hengrui Medicine**: Recent updates on lung cancer data show promising results, with an overall response rate (ORR) of 73% and median progression-free survival (mPFS) of 11.5 months, indicating strong commercial potential [16]. - **Innovative Drug Policies**: New policies are expected to encourage commercial insurance companies to invest in innovative drug companies and improve pricing standards [16][17]. Thematic Investment Lines - **Innovation and Overseas Expansion**: The report identifies innovative drugs as a key area, with a high success rate in recent insurance negotiations for innovative drugs [17]. - **Dividend Strategy**: With the 10-year government bond yield falling below 2%, dividend-paying assets with stable growth and cash flow are highlighted as defensive and offensive investment options [9][18]. Recommended Investment Combinations - The report lists several recommended stocks, including Hengrui Medicine, Enhua Pharmaceutical, and Yifan Pharmaceutical, among others, indicating a strong buy rating for these companies based on their growth potential and market performance [19][22].

Investment Rating - The report maintains a strong investment rating for the biopharmaceutical industry, particularly for the traditional Chinese medicine (TCM) sector, which is expected to benefit from multiple factors in 2025 [2]. Core Insights - The TCM sector is anticipated to experience a gradual reduction in performance pressure in 2025, driven by factors such as improved earnings, favorable policies, decreasing costs, rising demand, and consolidation within the industry [4][6]. - The report identifies five main investment opportunities within the TCM sector, including high-end OTC products, state-owned enterprise reforms, hospital-based TCM, dividend-paying assets, and turnaround situations for struggling companies [4][7]. Summary by Sections 1. Performance Outlook - The TCM sector faced overall revenue decline in 2024, with a total revenue of 270.61 billion yuan, down 3.28% year-on-year, and a net profit of 29.88 billion yuan, down 8.55% year-on-year [10]. - The number of companies forecasting negative net profit growth in 2024 is 22 out of 34, while only 12 companies expect positive growth [16]. 2. Policy Developments - The third batch of national TCM procurement results showed an average price reduction of 63%, but the impact on listed companies is limited due to the small number of affected products [20]. - A new essential drug list is expected to be released in 2025, which may include more TCM products, enhancing their market presence [24]. 3. Cost Factors - The TCM material price index has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies and improve their gross margins starting in 2025 [28]. 4. Demand Dynamics - The recent increase in flu cases has driven demand for related treatment products, leading to a quicker clearance of inventory for cold and cough medications [34]. 5. Competitive Landscape - The TCM industry is experiencing frequent mergers and acquisitions, which are likely to enhance industry concentration and provide performance flexibility for related listed companies [39]. 6. Investment Opportunities - The report highlights five key investment themes: 1. High-end OTC TCM products, particularly those using natural bezoar as a key ingredient, are expected to see improved margins as supply stabilizes [45][54]. 2. State-owned enterprise reforms are anticipated to yield positive changes in management and strategic planning [7]. 3. Hospital-based TCM products are expected to gain market share due to regulatory support [7]. 4. Companies with strong cash flow and high dividend potential are viewed favorably [7]. 5. Companies currently facing challenges are expected to improve as inventory pressures ease [7]. 7. Recommended Stocks - The report suggests monitoring companies such as Kunming Pharmaceutical, Tongrentang, Darentang, Jiangzhong Pharmaceutical, Dong'e Ejiao, China Resources Sanjiu, Yunnan Baiyao, Tianshili, Fangsheng Pharmaceutical, and others for potential investment opportunities [4].

一、国有股权无偿划转基本情况 重庆太极实业（集团）股份有限公司（以下简称：公司）于 2025 年 1 月 14 日披露了《关于间接控股股东国有股权无偿划转的提示性 公告》（公告编号：2025-004），公司间接控股股东中国中药有限公 司（以下简称：国药中药）与公司实际控制人中国医药集团有限公司 （以下简称：国药集团）签署了《关于太极集团有限公司 66.6666% 股权之无偿划转协议》，国药中药拟向国药集团无偿划转其持有的公 司控股股东太极集团有限公司（以下简称：太极有限）66.6666%股权。 本次无偿划转完成后，国药中药不再持有太极有限股权，国药集 团直接持有太极有限 66.6666%股权，并通过太极有限间接持有公司 29.82%的股权，国药集团仍为公司实际控制人。 证券代码：600129 证券简称：太极集团 公告编号 2025-007 重庆太极实业（集团）股份有限公司 关于间接控股股东国有股权无偿划转 完成市场监督管理局变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 二、本次国有股权无偿划转事项进展情况 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-006 特此公告。 重庆太极实业（集团）股份有限公司 2025 年 2 月 25 日 重庆太极实业（集团）股份有限公司 关于归还使用闲置募集资金补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 2024 年 8 月 21 日，重庆太极实业（集团）股份有限公司（以下 简称：公司）第十届董事会第二十二次会议审议通过了《关于使用部 分闲置募集资金暂时用于补充流动资金的议案》，同意公司使用不超 过 17,000 万元闲置募集资金暂时用于补充流动资金，使用期限为自 董事会审议通过之日起不超过 12 个月。具体内容详见公司 2024 年 8 月 23 日刊登于《中国证券报》《上海证券报》《证券时报》《证券 日报》及上海证券交易所网站（www.sse.com.cn）的公告（公告编号： 2024-041） 2025 年 2 月 21 日，公司归还用于暂时补充流动资金的闲置募集 资金 17,000 万元至公司募集资金专用账户，本次归还的募集资金使 用期限未超过 ...

Financial Performance - The company expects a net profit of approximately 156.4 million yuan for 2024, a decrease of about 665.7 million yuan, representing a year-on-year decline of approximately 80.98%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be around 134.21 million yuan, down about 640.2 million yuan, with a year-on-year decline of approximately 82.67%[2] - The total profit reported for 2023 was 1,026.6 million yuan, with a net profit attributable to shareholders of 822.1 million yuan[5] Revenue Expectations - The company anticipates a revenue decrease of approximately 3.213 billion yuan in 2024, reflecting a decline of 20.56%, with Q4 revenue expected to drop by about 1.464 billion yuan, a decline of 42.5%[6] R&D and Innovation - The company maintains a strong commitment to R&D investment, focusing on new product development and enhancing existing product lines through technological innovation[6] Operational Strategies - The company is actively optimizing its marketing model and strengthening operational control to improve sales performance[6] Non-recurring Items - Non-recurring gains and losses for 2024 are estimated to be around 22.19 million yuan, including government subsidies and asset disposal gains[6] Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[7] - The data provided is preliminary and subject to change pending the audited annual report for 2024[8]

2023年5月31日，太极集团盘中创下上市以来最高点68.44元。 中国经济网北京1月15日讯 太极集团(600129.SH)股价今日收盘报21.06元，跌幅4.19%。 海通证券股份有限公司研究员余文心、郑琴2023年6月1日发布研报《太极集团(600129)：国企改革激发 新动能 业绩潜力释放可期》称，给予太极集团"优于大市"评级。 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-004 重庆太极实业（集团）股份有限公司 关于间接控股股东国有股权无偿划转的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●太极集团有限公司（（以下简称：太极有限）为重庆太极实业（（集 团）股份有限公司（（以下简称：公司或太极集团）直接控股股东，持 有公司 153,812,354 股，占总股本的 27.62%，合并持有公司 29.82% 的股权。中国中药有限公司（以下简称：国药中药）持有太极有限 66.6666%股权，为公司间接控股股东，中国医药集团有限公司（（以下 简称：国药集团）为国药中药控股股东，持有国药中药 100%股权， 为公司实际控制人。 ●国药中药与国药集团签署了《关于太极集团有限公司 66.6666%股 权之无偿划转协议》，国药中药拟向国药集团无偿划转其持有的太极 有限 66.6666%股权（以下简称"本次交易"），本次无偿划转已获 得国药集团批准。 ●本次股份无偿划转的实施不会导致公司控股股东及实际控制人 发生变 ...

罗诗遂辞职不会影响公司经营管理的正常运行。 截至公告披露日，罗诗遂未持有公司股份，亦不存在应履行而未履行的承诺事项。 财联社1月6日电，太极集团公告，公司董事会于2025年1月3日收到公司副总经理罗诗遂的书面辞职报 告。 罗诗遂因达法定退休年龄，申请辞去公司副总经理职务，辞职后将不再担任公司任何职务。 根据相关规定，罗诗遂的辞职报告自送达公司董事会之日起生效。 ...